Tirz Rx vs Mounjaro vs Zepbound: what actually differs

Last updated 2026-07-27

What is the actual difference between Mounjaro, Zepbound, and compounded tirzepatide?

Mounjaro and Zepbound both contain tirzepatide, made by the same company, Eli Lilly. The molecule is identical. What differs is the FDA-approved indication printed on the label and, in the early years of each product, the marketing built around it. Mounjaro was approved in May 2022 for type 2 diabetes, based on the SURPASS trial program ^[1]. Zepbound was approved in November 2023 for chronic weight management, based on the SURMOUNT trial program ^[2]. Same injector pens, same dose steps (2.5 mg up to 15 mg weekly), same manufacturer. Lilly simply ran separate trials and got separate approvals because the FDA requires indication-specific evidence, even when the drug itself doesn't change. Compounded tirzepatide is a different category entirely. It's not FDA-approved as a finished product. Pharmacies (503A) or outsourcing facilities (503B) prepare it, typically as tirzepatide base powder reconstituted into a solution, under different regulatory rules than a Lilly-manufactured vial. The FDA's compounding statute (21 U.S.C. § 353a) allows this for legitimate clinical need, historically including drug shortages, but compounded product hasn't gone through the same standardized manufacturing review as Mounjaro or Zepbound ^[3]. Tirz Rx is not a pharmacy and doesn't compound or manufacture anything. It's a provider-reviewed platform: a licensed prescriber evaluates you, and if compounded tirzepatide is appropriate, the prescription is filled by a licensed pharmacy partner. That's a meaningfully different supply chain than picking a random overseas vendor selling "research chemical" tirzepatide with no prescriber involved at all.

How do Mounjaro and Zepbound differ in dosing?

They don't, really. Both start at 2.5 mg once weekly for four weeks as a tolerability run-in, then step up in 2.5 mg increments roughly every four weeks: 5 mg, 7.5 mg, 10 mg, 12.5 mg, up to a max of 15 mg weekly ^[4]. The titration schedule in both FDA labels is identical because it's the same drug studied in overlapping dose-ranging work. What differs slightly is how the labels talk about maintenance dosing. Zepbound's label frames 5 mg, 10 mg, and 15 mg as the studied maintenance doses for weight loss, since that's what SURMOUNT trials tested. Mounjaro's label does the same for glycemic control. In practice, a patient's actual titration is set by their prescriber based on tolerability, not by which brand name is on the pen. For readers using compounded tirzepatide, dosing follows the same general step-up logic but isn't standardized the same way across every provider or pharmacy. If you're working from a vial and syringe instead of a pre-filled pen, this is where it gets easy to make a real dosing error. Anyone starting compounded tirzepatide should look closely at Tirz Rx dosage guidance and, honestly, use a Tirz Rx dosage calculator rather than eyeballing a syringe.

What did the SURPASS trials show for Mounjaro (diabetes)?

The SURPASS program was the trial series that got Mounjaro approved for type 2 diabetes. Across the SURPASS-1 through SURPASS-5 trials, tirzepatide lowered HbA1c substantially more than comparators. In SURPASS-2 (NCT03987919), tirzepatide at 5, 10, and 15 mg was compared head-to-head against semaglutide 1 mg. HbA1c reductions were 2.01%, 2.24%, and 2.30% respectively for tirzepatide versus 1.86% for semaglutide 1 mg, and all three tirzepatide doses were statistically superior to semaglutide on this endpoint, published in the New England Journal of Medicine ^[5]. Weight loss in that same trial ran from about 7.6 kg to 11.2 kg across tirzepatide doses over 40 weeks, versus 5.7 kg on semaglutide. That head-to-head matters because semaglutide (Ozempic for diabetes, Wegovy for weight) is tirzepatide's closest competitor, and SURPASS-2 is one of the few big trials where the two drugs were tested directly against each other rather than against placebo. It's a big part of why tirzepatide gets talked about as the more potent of the two GLP-1 based drugs, though "more potent on average" doesn't mean every individual patient will do better on it.

What did the SURMOUNT trials show for Zepbound (weight loss)?

SURMOUNT-1 (NCT04184622) is the trial that anchors Zepbound's weight-loss approval. In adults with obesity or overweight plus a weight-related condition (excluding diabetes), 72 weeks of tirzepatide produced mean weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) from baseline, compared with 3.1% on placebo, published in NEJM ^[6]. Roughly half of participants on the 15 mg dose lost 20% or more of their body weight, a magnitude that starts to approach outcomes historically seen only with bariatric surgery. SURMOUNT-2 tested tirzepatide in adults with type 2 diabetes and obesity, and SURMOUNT-3 and SURMOUNT-4 looked at intensive lifestyle intervention run-ins and withdrawal effects. Across the program, the consistent finding is dose-dependent weight loss that keeps climbing through roughly 72 weeks before plateauing. One detail that matters for anyone thinking long-term: SURMOUNT-4 found that stopping tirzepatide after a lead-in period led to significant weight regain compared with staying on it, which is the same pattern seen with semaglutide withdrawal studies. This isn't a drug you take for three months and stop. It's built around continued use, and prescribers should be having that conversation up front, not as a surprise at month six.

How do the side effects compare between Mounjaro, Zepbound, and compounded versions?

The side-effect profile is the same regardless of which brand or compounding pathway delivers the drug. GI side effects dominate: nausea, diarrhea, vomiting, constipation. In SURMOUNT-1, nausea occurred in about 24-33% of tirzepatide-treated participants depending on dose, versus about 10% on placebo, and these effects were most common during dose escalation ^[6]. Both FDA labels carry a boxed warning about thyroid C-cell tumors, based on rodent studies where tirzepatide caused dose-dependent thyroid C-cell tumors. Mounjaro and Zepbound are both contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[4]. This is a boxed warning, the FDA's strongest label warning category, and it isn't optional screening. Anyone with that family history should not be on tirzepatide in any form, branded or compounded. Other labeled risks include acute pancreatitis, gallbladder disease (cholelithiasis and cholecystitis), acute kidney injury (often secondary to GI-fluid-loss-driven dehydration), hypersensitivity reactions, and hypoglycemia risk when combined with insulin or sulfonylureas ^[4]. Diabetic retinopathy complications have been flagged in related GLP-1 drug labels and are worth discussing with a prescriber if you have existing eye disease. Compounded tirzepatide carries the same pharmacologic risk profile as the branded product, but it adds a layer of manufacturing-consistency uncertainty that FDA-approved product doesn't have. A 503A or 503B facility isn't required to prove bioequivalence to Zepbound the way a generic drug maker would have to prove bioequivalence to a brand-name original. That's not automatically dangerous, but it's a real difference buyers should understand rather than assume away.

How much does Mounjaro cost compared to Zepbound and compounded tirzepatide?

List prices for both branded products run high without insurance. Mounjaro's list price is roughly $1,069.08 for a one-month supply according to Lilly's own pricing statements, and Zepbound has been listed at a similar range, though Lilly introduced a lower self-pay list price of $349-$499 per month for certain single-dose vial strengths purchased through its direct-to-consumer LillyDirect pharmacy channel starting in 2024 ^[7]. Insurance coverage varies enormously. Many commercial plans cover Mounjaro for type 2 diabetes with a prior authorization; far fewer cover Zepbound for weight loss alone, and Medicare has historically excluded weight-loss drugs from Part D coverage under the statutory exclusion for "agents used for weight loss" (Social Security Act § 1927(d)(2)), though CMS guidance on this has been evolving. Compounded tirzepatide, filled through a licensed pharmacy after a provider evaluation, generally runs cheaper per month than branded list price, which is the main reason it exists as an access category at all: cash-pay patients priced out of Zepbound or Mounjaro. Costs vary by pharmacy and dose, and this article won't give a false-precision number since pricing shifts by provider and region. If cost is the driver, it's worth actually comparing your specific quote against Lilly's current self-pay vial pricing before assuming compounded is automatically the cheaper route; sometimes it is, sometimes it isn't anymore. | Product | Approved for | Maker | Typical monthly list price |

Is compounded tirzepatide legal and is it safe?

Compounding is legal under specific, narrow conditions. Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353a) allows licensed pharmacies to compound a drug for an individual patient with a valid prescription, without going through the full new-drug approval process, provided they meet conditions around not compounding copies of commercially available products under most circumstances ^[3]. Section 503B allows outsourcing facilities to compound at larger scale under current good manufacturing practice oversight, often used to fill shortage-driven demand. The FDA maintained tirzepatide on its drug shortage list for an extended period through 2022-2023, which is what opened the door for widespread compounding in the first place; compounding copies of an approved drug that isn't in shortage is generally restricted under 503A. As of late 2024 the FDA removed tirzepatide from the shortage list, which triggered legal challenges and a wind-down period for compounders, and the regulatory landscape here has kept shifting, so anyone relying on compounded tirzepatide should expect availability and legal footing to keep changing rather than assume today's rules hold indefinitely. "Safe" depends heavily on which pharmacy compounds it. A state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility working from pharmaceutical-grade tirzepatide, under a real prescriber's oversight, is a very different risk profile than an unlicensed overseas seller shipping vials with no prescription and no quality testing. The FDA has issued public warnings about counterfeit and substandard compounded semaglutide and tirzepatide products, including some containing the wrong salt form of the drug entirely ^[8]. This is the single biggest reason to route compounded tirzepatide through a provider-reviewed pathway with a named, licensed fulfilling pharmacy rather than an anonymous website.

How does tirzepatide compare to semaglutide (Ozempic/Wegovy) overall?

Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is GLP-1 only. That mechanistic difference is the likely reason tirzepatide outperformed semaglutide on both HbA1c and weight loss in the SURPASS-2 head-to-head ^[5]. In cross-trial comparisons (not head-to-head, so read with caution), semaglutide 2.4 mg in the STEP 1 trial produced about 14.9% mean weight loss at 68 weeks , compared to tirzepatide's 15-20.9% range across doses in SURMOUNT-1 over 72 weeks ^[6]. That's a real difference, but it's not a landslide, and individual response varies more than the trial averages suggest. Some patients do better on semaglutide, tolerate it better, or simply can't access tirzepatide due to cost or supply. Side-effect profiles are broadly similar (GI-dominant), and both carry the same thyroid C-cell boxed warning class-wide. If you're choosing between the two purely on trial data, tirzepatide has the edge on average magnitude of both glycemic and weight effects. If you're choosing on access, cost, or how your body specifically responds, the trial averages matter less than your own trial-of-one.

What should I know about starting and injecting tirzepatide?

Whether you're on branded Zepbound pens or a compounded vial, injection technique matters for both comfort and dose accuracy. Subcutaneous injection into the abdomen, thigh, or upper arm is standard, rotating sites to reduce irritation and lipohypertrophy risk over time. If you're using a vial-and-syringe setup rather than a pre-filled pen, you need to know how to reconstitute the powder correctly if it arrives lyophilized, draw an accurate dose, and inject it properly. These aren't steps to guess at. Review how to reconstitute Tirz Rx and Tirz Rx how to inject guidance before your first dose, and check Tirz Rx injection sites for rotation practices that reduce site reactions. Most people also want to know how long a course of treatment should run. Given the SURMOUNT-4 withdrawal data showing weight regain after stopping, this isn't a short-course drug for most patients pursuing weight loss; it's closer to a chronic-management medication, similar to how you'd think about a blood pressure drug. Anyone planning their timeline should read up on Tirz Rx cycle length considerations before assuming a fixed stop date.

Where does Tirz Rx fit into this comparison?

Tirz Rx doesn't make Mounjaro, doesn't make Zepbound, and doesn't compound tirzepatide itself. It's a provider-reviewed platform: you get evaluated by a licensed prescriber, and if compounded tirzepatide is judged appropriate for you, the prescription is filled by a licensed pharmacy partner, not by Tirz Rx directly. The honest comparison for a reader deciding among these three paths comes down to three questions: Do I need the FDA-approved product specifically, does my insurance cover Mounjaro or Zepbound, and if not, am I comfortable with a provider-reviewed compounded pathway instead of an unregulated one. There's no universally right answer. Someone with good insurance coverage for Zepbound has little reason to look at compounded product. Someone paying cash, priced out of both branded options, has a real decision to make about which compounding pathway has actual prescriber oversight and a named, licensed pharmacy behind it versus one that doesn't.

Frequently asked questions

Is Mounjaro the same drug as Zepbound?

Yes. Both contain tirzepatide, made by Eli Lilly, at the same dose range (2.5 mg to 15 mg weekly). Mounjaro is FDA-approved for type 2 diabetes based on the SURPASS trials; Zepbound is FDA-approved for chronic weight management based on the SURMOUNT trials. The molecule and injector devices are the same across both.

Can I use Mounjaro for weight loss instead of Zepbound?

Physicians can prescribe Mounjaro off-label for weight loss, and this happens often, especially when insurance covers Mounjaro but not Zepbound. It's the same drug, so the pharmacologic effect is the same. The difference is purely which FDA-approved indication is on the label, not the drug itself.

Is compounded tirzepatide as effective as Zepbound or Mounjaro?

Compounded tirzepatide should work the same way pharmacologically if it contains accurately dosed tirzepatide, since it's the same molecule. The uncertainty isn't efficacy of the drug itself, it's manufacturing consistency: compounded product hasn't gone through FDA's standardized approval process, so quality depends heavily on which pharmacy makes it.

What is the boxed warning on tirzepatide about?

Both Mounjaro and Zepbound carry an FDA boxed warning for thyroid C-cell tumors, based on findings in rodent studies. Tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is the strongest warning category the FDA uses.

How much weight can you lose on tirzepatide?

In the SURMOUNT-1 trial, participants without diabetes lost a mean of 15.0% to 20.9% of body weight over 72 weeks, depending on dose (5, 10, or 15 mg), versus 3.1% on placebo. Roughly half of participants on the 15 mg dose lost 20% or more of their starting body weight.

Does tirzepatide work better than Ozempic or Wegovy?

In the SURPASS-2 head-to-head trial, tirzepatide beat semaglutide 1 mg on both HbA1c reduction and weight loss. Tirzepatide isn't universally superior for every patient, but on trial averages it produced larger effects, likely because it acts on both GIP and GLP-1 receptors instead of GLP-1 alone.

Is compounded tirzepatide legal right now?

Compounding law (21 U.S.C. § 353a) allows licensed pharmacies to compound patient-specific prescriptions under certain conditions, generally restricted when a commercial version isn't in shortage. The FDA removed tirzepatide from its drug shortage list in late 2024, which triggered legal disputes and a wind-down affecting compounders. Rules here keep shifting; check current FDA guidance rather than assuming a fixed status.

What are the most common side effects of tirzepatide?

GI side effects dominate: nausea, diarrhea, vomiting, and constipation, most common during dose escalation. In SURMOUNT-1, nausea affected roughly 24-33% of tirzepatide patients versus about 10% on placebo. Other labeled risks include gallbladder disease, pancreatitis, kidney injury from dehydration, and hypoglycemia when combined with insulin or sulfonylureas.

How much does Zepbound cost without insurance?

Zepbound's list price has historically run near $1,000+ per month for pens, but Lilly introduced lower self-pay vial pricing of roughly $349 to $499 per month for certain dose strengths through its LillyDirect channel starting in 2024. Actual cost depends heavily on dose, pharmacy channel, and whether insurance covers any portion.

Does Medicare cover Zepbound or Mounjaro?

Medicare Part D has historically excluded weight-loss drugs from coverage under a statutory exclusion for weight-loss agents, which affected Zepbound access for many beneficiaries. Mounjaro, approved for type 2 diabetes, has generally had better Part D coverage odds since diabetes drugs aren't subject to that same exclusion. Coverage policy has been shifting, so check current plan formularies directly.

What happens if you stop taking tirzepatide?

The SURMOUNT-4 trial found that participants who stopped tirzepatide after a lead-in period regained significant weight compared with those who continued treatment. This mirrors findings with semaglutide withdrawal. Tirzepatide is generally treated as a long-term management medication rather than a short course, similar to how blood pressure or cholesterol medications are used.

How do I know if a compounded tirzepatide pharmacy is legitimate?

Look for a named, state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility, a real prescriber evaluation before any prescription is issued, and transparency about where the product is compounded. The FDA has warned about counterfeit and substandard compounded tirzepatide, including wrong-salt-form products, sold without any prescriber oversight at all.

Sources

1. FDA, Mounjaro approval letter and label history: Mounjaro was approved in May 2022 for type 2 diabetes
2. Cornell Law School, Legal Information Institute, 21 U.S.C. § 353a: Federal compounding statute conditions under which pharmacies may compound patient-specific prescriptions
3. FDA, Zepbound prescribing information: Tirzepatide dosing titration schedule and boxed warning for thyroid C-cell tumors, contraindication in MEN2/MTC
4. New England Journal of Medicine, SURPASS-2 trial (NCT03987919): Tirzepatide HbA1c and weight loss results compared head-to-head against semaglutide 1 mg
5. New England Journal of Medicine, SURMOUNT-1 trial (NCT04184622): Tirzepatide produced 15.0% to 20.9% mean weight loss over 72 weeks versus 3.1% on placebo
6. Eli Lilly, Mounjaro and Zepbound pricing information: Mounjaro and Zepbound list prices and LillyDirect self-pay vial pricing
7. FDA, warning on counterfeit and compounded semaglutide/tirzepatide products: FDA warnings about counterfeit and substandard compounded GLP-1/GIP products, including wrong salt forms
8. New England Journal of Medicine, STEP 1 trial: Semaglutide 2.4 mg produced approximately 14.9% mean weight loss at 68 weeks